Metagenomi (MGX) News Today → America’s worst nightmare? (From Porter & Company) (Ad) Free MGX Stock Alerts $6.55 0.00 (0.00%) (As of 05/13/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 9, 2024 | americanbankingnews.comMetagenomi, Inc. Expected to Earn Q1 2024 Earnings of ($1.20) Per Share (NASDAQ:MGX)May 8, 2024 | msn.comHC Wainwright & Co. Initiates Coverage of Metagenomi (MGX) with Buy RecommendationMay 8, 2024 | americanbankingnews.comMetagenomi (NASDAQ:MGX) Now Covered by Analysts at HC WainwrightMay 7, 2024 | marketbeat.comMetagenomi (NASDAQ:MGX) Research Coverage Started at HC WainwrightHC Wainwright started coverage on shares of Metagenomi in a research report on Tuesday. They issued a "buy" rating and a $10.00 price objective on the stock.May 6, 2024 | americanbankingnews.comMetagenomi (NASDAQ:MGX) Lowered to "Neutral" at JPMorgan Chase & Co.May 4, 2024 | msn.comJ.P. Morgan downgrades Metagenomi over Moderna deal terminationMay 2, 2024 | markets.businessinsider.comAnalyst Maintains ‘Buy’ Rating on Metagenomi Amidst New Opportunities Post-Moderna Partnership TerminationMay 2, 2024 | marketbeat.comTrading was temporarily halted for "MGX" at 09:05 AM with a stated reason of "LULD pause."May 2, 2024 | marketbeat.comMetagenomi (NASDAQ:MGX) Rating Lowered to Neutral at JPMorgan Chase & Co.JPMorgan Chase & Co. downgraded Metagenomi from an "overweight" rating to a "neutral" rating and decreased their price objective for the company from $16.00 to $6.00 in a research report on Thursday.May 2, 2024 | investorplace.com3 Gene Editing Stocks with the Potential to Make You an Overnight MillionaireMay 1, 2024 | globenewswire.comMetagenomi to regain full development rights to its wholly-owned base editing and RIGS systemsApril 8, 2024 | globenewswire.comMetagenomi to Present at Upcoming Scientific MeetingsApril 4, 2024 | marketbeat.comMetagenomi, Inc. Expected to Earn FY2024 Earnings of ($2.44) Per Share (NASDAQ:MGX)Metagenomi, Inc. (NASDAQ:MGX - Free Report) - Chardan Capital issued their FY2024 earnings estimates for Metagenomi in a note issued to investors on Monday, April 1st. Chardan Capital analyst G. Livshits forecasts that the company will post earnings per share of ($2.44) for the year. Chardan CapiApril 3, 2024 | fool.comMetagenomi (NASDAQ: MGX)April 2, 2024 | morningstar.comMetagenomi Inc MGXMarch 29, 2024 | markets.businessinsider.comMetagenomi, Inc.: Strong Buy Rating on Robust Hemophilia Program and Strategic PartnershipsMarch 29, 2024 | markets.businessinsider.comMetagenomi, Inc.: Strong Buy Rating on Promising Pipeline and Solid Financial PositioningMarch 28, 2024 | finanznachrichten.deMetagenomi, Inc.: Metagenomi Reports Business Updates and Full Year 2023 Financial ResultsMarch 28, 2024 | marketbeat.comMetagenomi (NASDAQ:MGX) Stock Rating Reaffirmed by Chardan CapitalChardan Capital reissued a "buy" rating and set a $21.00 price target on shares of Metagenomi in a report on Thursday.March 27, 2024 | msn.comMetagenomi reports FY resultsMarch 27, 2024 | globenewswire.comMetagenomi Reports Business Updates and Full Year 2023 Financial ResultsMarch 5, 2024 | marketbeat.comMetagenomi, Inc. (NASDAQ:MGX) Given Consensus Rating of "Buy" by BrokeragesMetagenomi, Inc. (NASDAQ:MGX - Get Free Report) has been given a consensus recommendation of "Buy" by the six analysts that are currently covering the company, MarketBeat reports. Six investment analysts have rated the stock with a buy rating. The average 1-year price target among analysts that haMarch 5, 2024 | marketbeat.comMetagenomi (NASDAQ:MGX) Coverage Initiated at TD CowenTD Cowen initiated coverage on shares of Metagenomi in a research note on Tuesday. They issued an "outperform" rating for the company.February 29, 2024 | globenewswire.comMetagenomi to Participate in the 44th Annual Cowen Healthcare ConferenceFebruary 19, 2024 | fool.comThis Biotech IPO Stock Just Took a Tumble, But Don't Give Up on It YetFebruary 18, 2024 | 247wallst.comInsider Buying: Taking a Controlling Stake in a Struggling Retailer?February 13, 2024 | globenewswire.comMetagenomi Announces Closing of Initial Public OfferingFebruary 9, 2024 | reuters.comModerna, Bayer-backed Metagenomi stock drops 32% on Nasdaq debut Get Metagenomi News Delivered to You Automatically Sign up to receive the latest news and ratings for MGX and its competitors with MarketBeat's FREE daily newsletter. Email Address Does this chart look familiar? (Ad)Investors who understand when to get in — and when to get out… Can make a lot of money. Like in the chart, I showed you above… Get all the information here. MGX Media Mentions By Week MGX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MGX News Sentiment▼1.000.57▲Average Medical News Sentiment MGX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MGX Articles This Week▼72▲MGX Articles Average Week Get Metagenomi News Delivered to You Automatically Sign up to receive the latest news and ratings for MGX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Fennec Pharmaceuticals News Today Monte Rosa Therapeutics News Today Poseida Therapeutics News Today Sutro Biopharma News Today Coherus BioSciences News Today Agenus News Today Adaptimmune Therapeutics News Today Invivyd News Today Candel Therapeutics News Today Opthea News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MGX) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsElon’s New Device is About to Shock the WorldInvestorPlaceCharles Payne Demystifies OptionsUnstoppable ProsperityNot Trump. Not Biden. But ___________.The Freeport SocietyTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressGold ManiaStansberry ResearchThe only AI company you should be looking atBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Metagenomi, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
